Floatz logo

Therapeutic Asset Ratings

1,027 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Inotuzumab Ozogamicin
ph+ Acute Lymphoblastic Leukemia
University of ChicagoP2CCC (53)
Inotuzumab Ozogamicin
Precursor Lymphoblastic Lymphoma/Leukemia
Institute of Hematology & Blood Diseases Hospital, ChinaP2CCC (53)
Ladiratuzumab Vedotin
Angiosarcoma
QuantumLeap Healthcare CollaborativeP2CCC (53)
Ladiratuzumab Vedotin
Hormone Receptor Negative Tumor
QuantumLeap Healthcare CollaborativeP2CCC (53)
Ladiratuzumab Vedotin
Hormone Receptor Positive Tumor
QuantumLeap Healthcare CollaborativeP2CCC (53)
Maridebart Cafraglutide
Overweight or Obesity and Elevated Liver Fat
AmgenP2CCC (53)
Mirvetuximab Soravtansine
Fallopian Tube Disorder
University of Alabama at BirminghamP2CCC (53)
Mirvetuximab Soravtansine
Folate Receptor-Alpha Positive
AbbVieP2CCC (53)
Mirvetuximab Soravtansine
Neoadjuvant
AbbVieP2CCC (53)
Mirvetuximab Soravtansine
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
AGO Research GmbHP2CCC (53)
Mirvetuximab Soravtansine-GYNX
Ovarian Cancer
University of Colorado, DenverP2CCC (53)
Mirvetuximab Soravtansine-GYNX
Peritoneum Cancer
University of Colorado, DenverP2CCC (53)
Mylotarg
Acute Promyelocytic Leukemia
Associazione Italiana Ematologia Oncologia PediatricaP2CCC (53)
Polatuzumab Vedotin
Bispecific Antibody
Li ZhimingP2CCC (53)
Polatuzumab Vedotin
Heart Disorder
Beth Israel Deaconess Medical CenterP2CCC (53)
Polatuzumab Vedotin
Neoplasm
The First Affiliated Hospital of Soochow UniversityP2CCC (53)
Polatuzumab Vedotin
Nodal Marginal Zone B-Cell Lymphoma
SWOG Cancer Research NetworkP2CCC (53)
Polatuzumab Vedotin
Splenic Marginal Zone Lymphoma
SWOG Cancer Research NetworkP2CCC (53)
Polatuzumab Vedotin
Safety Issues
The First Affiliated Hospital of Soochow UniversityP2CCC (53)
Polatuzumab Vedotin
Transformed Follic Lymph to Diff Large B-Cell Lymphoma
SWOG Cancer Research NetworkP2CCC (53)
rc48
Disitamab Vedotin
Sun Yat-sen UniversityP2CCC (53)
rc48
ERBB2 Mutation-Related Tumors
Sun Yat-sen UniversityP2CCC (53)
rc48
Fallopian Tube Carcinoma
Peking University Cancer Hospital & InstituteP2CCC (53)
rc48
HER2 Positive Breast Carcinoma
Zhejiang Cancer HospitalP2CCC (53)
rc48
Cutaneous Paget Disease
Fudan UniversityP2CCC (53)
Showing 376 to 400 of 1,027 assets
PreviousPage 16 of 42Next